1. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease†
- Author
-
Ludwig Deml, Johann Leban, Aldo Ammendola, Claudia Hofmann, Leo R. Fitzpatrick, Jeffrey S. Small, Manfred Groeppel, Svetlana Hamm, and Sylvia Lemstra
- Subjects
Oxidoreductases Acting on CH-CH Group Donors ,medicine.medical_treatment ,Blotting, Western ,Dihydroorotate Dehydrogenase ,Lymphocyte proliferation ,Inflammatory bowel disease ,Peripheral blood mononuclear cell ,Immunoenzyme Techniques ,Mice ,In vivo ,Animals ,Immunology and Allergy ,Medicine ,Dicarboxylic Acids ,Colitis ,Cell Proliferation ,Mice, Inbred BALB C ,business.industry ,Biphenyl Compounds ,Dextran Sulfate ,Interleukin-17 ,Gastroenterology ,Inflammatory Bowel Diseases ,medicine.disease ,Disease Models, Animal ,Cytokine ,Immunosuppressive drug ,Trinitrobenzenesulfonic Acid ,Acute Disease ,Chronic Disease ,Immunology ,Female ,Interleukin 17 ,business ,Immunosuppressive Agents - Abstract
Background: Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases. 4SC-101 is a novel immunosuppressive drug that inhibits DHODH. A goal of our study was to examine the in vitro effects of 4SC-101 on IL-17 production by mononuclear cells. In addition, we evaluated the efficacy of 4SC-101 against acute TNBS (2,4,6-tritrobenzene sulfonic acid) and chronic dextran sodium sulfate (DSS)-induced colitis in mice. Methods: Peripheral blood mononuclear cells (PBMCs) from healthy human donors were used to evaluate cellular proliferation and cytokine (IL-17, TNF-α) production. The oral effects of 4SC-101 (100 or 200 mg/kg) were examined following induction of chronic colitis by the administration of 3% DSS (4 cycles) to Balb/c mice. Morphometric and histological indices of colitis were evaluated as indicators of drug efficacy. 4SC-101 was also administered for 6 days after the intracolonic administration of TNBS (20 mg in 50% ethanol) to female Balb/c mice. The colons were analyzed for overall macroscopic damage, ulceration, total length, distal segment weight, MPO activity, and histological pathology as indicators for the effectiveness of 4SC-101. Results: In vitro, 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes. In vivo, oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. In these colitis models the overall efficacy profile of 4SC-101 was similar to that of dexamethasone. Conclusions: 4SC-101 is a novel immunosuppressive drug with excellent potential for the treatment of intestinal inflammation. (Inflamm Bowel Dis 2010)
- Published
- 2010